News und Analysen

Earlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug candidate remibrutinib for a skin condition known

Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend income. The trick is diversifying across top businesses in numerous industries to

One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:

For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an

Novartis (NYSE: NVS) enjoyed a strong rally today, as the Swiss drugmaker announced an improved revenue forecast for 2023 and a massive share repurchase program. Specifically, the drugmaker's stock

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q2 2023 Earnings CallJul 18, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical

Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one

Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to

Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis. 

Chinook is a

Novartis (NYSE: NVS) is a company in transition. Over the past several years, the Swiss multinational pharma giant has been busy divesting key assets such as its eye care unit Alcon, trimming costs

Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's

Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated